查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854005

細胞和基因治療臨床試驗市場（按治療類型、載體類型、細胞類型、適應症和試驗階段分類）—2025-2032年全球預測

Cell & Gene Therapy Clinical Trials Market by Therapy Type, Vector Type, Cell Type, Indication, Trial Phase - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，細胞和基因治療臨床試驗市場將成長至 323.8 億美元，複合年成長率為 15.14%。

關鍵市場統計數據
基準年2024年 104.8億美元
預計年份：2025年 120.8億美元
預測年份 2032 323.8億美元
複合年成長率 (%) 15.14%

全面介紹影響細胞和基因治療臨床試驗及策略計畫選擇的臨床、生產和監管因素。

細胞和基因治療臨床試驗生態系統正處於關鍵的十字路口，其發展受到快速的科學成熟、不斷變化的監管預期以及不斷變化的商業性需求的共同影響。過去十年，細胞工程、病毒和非病毒遞送平台以及製程分析的創新催生了更廣泛、更多樣化的研發管線。因此，曾經專注於自體療法的計畫如今正轉向異體療法、複雜的載體設計以及融合分散式和集中式能力的混合生產模式。

在這種環境下，相關人員需要在科學抱負與切實可行的營運計畫之間取得平衡。申辦者必須將臨床開發設計與供應鏈韌性、載體採購安全性和生產擴充性結合。投資者和合作夥伴機構正日益仔細地審查開發路徑，以明確轉化風險、監管合規性和商業化準備。因此，能夠將強大的轉化科學與可驗證的生產計劃和監管關係相結合的臨床試驗贊助者，將能夠高效地推進治療方法進入臨床並最終獲得應用。

鑑於生物學、物流和政策之間錯綜複雜的相互作用，將治療方式、載體策略、細胞類型選擇、適應症優先排序和臨床試驗階段順序聯繫起來的整體觀點至關重要。本報告將這些維度整合為一個連貫的敘述，為貫穿整個研發生命週期的專案策略決策和營運執行提供支援。

研發模式、生產自動化和監管科學的突破如何重新定義臨床研發路徑和商業化準備

由於遞送系統、生產自動化和監管科學的進步，細胞和基因療法的臨床開發模式正在發生顯著變化。遞送技術正從傳統的病毒載體擴展到更先進的非病毒載體，例如電穿孔和脂質奈米顆粒系統，從而實現更安全、更靈活的基因轉移策略，並開拓新的適應症。同時，載體工程和衣殼設計的創新正在改善組織靶向性和免疫抗原性原性，促使臨床項目重新思考以往關於治療方法和患者選擇的決策。

生產現代化同樣至關重要。採用封閉式系統、一次性技術和強化純化策略，提高了製程穩健性和可重複性的標準。這些改進降低了批次差異，縮短了週期時間，並促進了自體和異體模型的規模化應用。監管機構也積極回應，完善了效力檢測法、可比性框架和長期追蹤要求的指導，敦促臨床團隊將監管考慮融入早期研究設計中。

最後，商業和臨床策略正朝著適應症特異性最佳化方向發展。腫瘤研發管線正日益轉向針對骨髓惡性腫瘤和固態腫瘤的差異化治療方案，而神經病學和罕見疾病計畫則致力於實現持續的中樞神經系統給藥和單劑量治療。總而言之，這些轉變需要整合研發計劃，將科學創新與可生產性、監管途徑和長期患者用藥策略相結合。

評估關稅引發的供應鏈壓力和成本上漲對臨床試驗連續性和生產方案的營運和策略影響

近期貿易政策的發展以及2025年關稅的實施，為細胞和基因治療臨床計畫的規劃計算引入了新的變數。關稅對關鍵投入品、專用設備和跨境服務的累積影響，凸顯了供應鏈透明度和供應商多元化的重要性。實驗室和製造商在採購病毒載體、一次性耗材和高等級試劑時，如今更加密切地評估總土地成本和前置作業時間波動，這影響著他們選擇國內採購還是國際採購，以及是否需要儲備更多符合GMP標準的物料安全庫存。

為此，各組織正加快推進關鍵供應鏈本地化，並對載體生產、關鍵原料和生物加工設備的二級供應商合格。這一趨勢與對本地生產能力的策略性投資以及與合約研發受託製造廠商）的合作相輔相成，從而降低關稅相關中斷帶來的風險。同時，關稅帶來的成本壓力也獎勵企業致力於製程最佳化和產量比率提升，以降低每劑疫苗的材料消費量和對進口成分的依賴。

從營運角度來看，申辦方正在調整臨床試驗預算，以應對日益複雜的物流、潛在的海關延誤以及不斷上漲的低溫運輸運輸成本。這些調整會影響試驗中心的選擇、受試者招募策略以及多區域試驗的時間表。總而言之，關稅政策的變化凸顯了製定動態臨床實驗鏈策略、與製造商和物流供應商密切合作以及進行情境規劃的必要性，以確保試驗的連續性和臨床進展。

利用綜合細分框架，將治療方式、載體技術、細胞來源、適應症和臨床試驗階段連結起來，從而優先制定臨床和生產策略。

細緻的細分方法揭示了治療方式、載體技術、細胞來源、適應症和臨床階段如何相互交織，從而影響專案的風險和機會。根據治療類型，該領域涵蓋細胞療法、基因療法和組織工程產品。細胞療法計畫進一步細分為CAR-T細胞療法、樹突細胞療法、NK細胞療法和幹細胞療法。基因療法策略分為非病毒載體和病毒載體，其中非病毒載體包括電穿孔、脂質奈米顆粒和裸核酸等方法，病毒載體包括腺結合病毒、腺病毒和逆轉錄病毒系統等。這種分層分類法闡明了科學選擇如何影響生產的複雜性和監管參與。

對載體類型進行分類，包括非病毒載體和病毒載體，是風險評估的基礎。雖然病毒載體具有高效基因轉移和持久表達的優勢，但載體遞送、免疫反應和衣殼選擇等方面仍需考慮。對細胞類型進行分類則突顯了操作上的權衡取捨。樹突細胞和NK細胞的療效檢測方法和給藥方案各不相同；幹細胞需要譜系特異性處理，並分為造血幹細胞和間質幹細胞亞型；T細胞策略則分為CAR-T細胞和TCR細胞，二者在生產和臨床監測方面存在差異。

基於適應症的細分闡明了治療意圖如何定義臨床設計。針對阿茲海默症和帕金森氏症的神經病學計畫面臨著血腦障壁遞送和長期安全性監測的需求。腫瘤學研究必須區分血液系統癌症（如白血病和淋巴瘤）與固體癌（如乳癌和黑色素瘤），尤其是在腫瘤微環境調控方面。以遺傳和代謝性疾病（如囊腫纖維化和血友病）為中心的罕見疾病研究優先考慮持續的性能改進和新生兒篩檢的整合。從I期到III期的臨床試驗細分凸顯了日益提高的監管期望、對商業規模生產計劃日益成長的需求，以及證據重點從安全性和概念驗證轉向更廣泛的療效、持久性和真實世界應用性。這些細分視角為優先考慮研發投資和管理資源的分配提供了一個全面的框架。

區域法律規範、生產能力和臨床基礎設施如何驅動具有全球影響力的差異化發展策略

區域因素對研究設計、製造地和監管規劃等策略決策有顯著影響。在美洲，成熟的投資者基礎和完善的臨床基礎設施推動了早期和晚期項目的開展，集中了血液腫瘤領域的專業知識和先進的生產製造創新，支持自體和異體移植。該地區的監管工作日益側重於長期安全性監測和核准後承諾，這些因素正在影響證據產生計畫和後續方案的發展。

在歐洲、中東和非洲，監管環境既存在協調統一的機遇，也存在各國差異。歐洲監管機構和衛生技術評估機構需要可靠的療效和安全性比較數據，這些數據會影響終點選擇和伴隨診斷策略。同時，這些地區的新興市場擁有極具吸引力的罕見疾病和神經病學臨床試驗患者群體，但需要在倫理、基礎設施準備和供應鏈物流方面進行周密規劃。

亞太地區的特點是產能快速擴張、公共對生物製造的定向投資，以及臨床試驗中心數量不斷增加，這些中心在基因和細胞治療研究方面經驗日益豐富。各地法律規範正在不斷發展以適應先進療法，各國政府鼓勵發展國內生產能力以加速區域市場准入，但這可能也會在智慧財產權和人才方面造成動態。在整個亞太地區，申辦方都在努力平衡臨床試驗速度、監管合規性和本地營運可行性，以成功實施其全球發展策略。

高績效組織如何透過平台專業化、策略製造夥伴關係以及整合轉換和商業規劃脫穎而出

細胞和基因治療領域的主要企業和機構在技術平台、生產模式和治療重點領域均展現出策略多元化。一些公司專注於載體設計、衣殼工程和非病毒遞送系統等平台技術，從而能夠跨多個專案共用研發和製程開發投資。另一些機構則優先考慮細胞類型專業化，致力於在幹細胞分化、NK細胞生物學和T細胞工程方面積累深厚的專業知識，以在特定適應症中獲得臨床和轉化優勢。

與合約開發和受託製造公司的合作關係日益趨向於長期策略聯盟，其中包括聯合製程最佳化、技術轉移和共用生產力計畫。企業也在投資內部生產，因為對關鍵品質屬性和時間節點的控制是其提案主張的核心，同時選擇性地進行外包，以保持靈活性和成本控制。智慧財產權策略優先考慮載體平台和給藥方式的自由，許多公司正在利用生物標記特徵和數位試驗終點等數據主導資產來補充其核心智慧財產權，以加強與監管機構和支付方的互動。

最後，該領域的領導力通常與將轉化科學與商業性遠見結合的能力密切相關。在研發早期就協調好臨床方案、生產規模化和市場推廣計畫的團隊，能夠減少後續環節的摩擦，並加速病患獲得治療的速度。

優先營運建議，旨在加強供應鏈、標準化平台，並協調監管和商業計劃，以實現專案的持續成功。

產業領導者應採取一系列切實有效、影響深遠的行動，以克服科學上的複雜性和營運上的限制。首先，在專案規劃中建構供應鏈韌性，具體措施包括：確定多個載體和關鍵材料供應商；投資建設符合GMP標準的耗材策略庫存緩衝；以及評估區域生產夥伴關係關係，以降低貿易中斷的風險。其次，加快平台協調：在所有產品組合中標準化核心單元操作、檢測方法和效力指標，以縮短研發週期並簡化可比性評估。

第三，儘早與監管機構溝通，為臨床和生產決策提供資訊。及時與監管機構展開對話，明確長期追蹤預期、可比較標準以及新型遞送系統的要求。即使載體和細胞產量只有小幅提升，也能顯著降低下游物流負擔和成本敏感度。第五，制定商業策略，將健康經濟學終點和真實世界數據收集納入關鍵試驗設計和核准後計劃，從而滿足支付方的證據需求。

最後，透過投資組成能夠連結生物學、程式工程、法規事務和市場進入領域的團隊，發展跨職能能力。這種組織上的協調一致有助於在不確定性下更快地做出決策，更順暢地進行技術轉移，並在與合作夥伴和支付方的談判中佔據更有利的地位。實施這些措施將有助於確保近期臨床試驗的順利進行，並最終實現長期的商業成功。

結合專家訪談、監管審查和情境分析的穩健混合方法，能夠提供針對具體項目且具有實際操作意義的見解。

本分析的調查方法採用定性方法，整合臨床開發趨勢、監管指南審查和跨行業商業實踐，以得出可操作的見解。主要資料來源包括對臨床開發負責人、生產和供應鏈高管以及監管事務專家的結構化訪談，並輔以同行評審文獻、監管文件和產品特定技術披露。分析重點在於透過資訊來源交叉驗證，以檢驗觀察到的變化，包括給藥技術、流程改善和區域產能擴張。

分析師應用了一個細分框架，該框架整合了治療方式、載體類型、細胞生物學、適應症和臨床試驗階段，以確保提供特定情況的建議。情境分析用於評估貿易政策變化、供應鏈衝擊和製造創新對臨床實驗連續性和專案經濟效益的影響。在條件允許的情況下，方法論透明化，記錄了關於供應鏈依賴性、監管時間表和技術成熟度水準的假設。

調查方法的局限性包括：快速變化的臨床數據和獨特的生產流程可能會改變專案進度軌跡，而地方監管決策也可能根據新出現的證據進行調整。為了彌補這些局限性，該方法強調定期更新建議，並提供針對特定項目和夥伴關係情況的深入分析選項。

一份簡明扼要的策略要務概要，旨在將科學創新與營運韌性相結合，以推進臨床項目並改善患者就醫途徑。

總之，細胞和基因治療臨床試驗領域正處於曲折點，科學機會與日益複雜的運作環境交匯融合。遞送技術、載體工程和生產自動化方面的進步正在為更廣泛的治療效果鋪平道路，但這些進步也伴隨著供應鏈脆弱性、監管審查以及對規模化生產解決方案的需求。積極整合治療方式選擇、載體策略、細胞來源考量、適應症特異性設計以及符合各階段研究證據產生的申辦方，將能更有效地降低研發風險。

區域動態和近期貿易政策發展進一步凸顯了建構具有韌性的供應鏈、多元化的製造地以及精心安排的監管合作的重要性。成功的專案需要組建跨職能團隊，將轉化科學與製程開發和商業性遠見相結合，並執行複雜且相互關聯的目標。最終，那些盡可能優先考慮標準化、在必要時保持靈活性並與監管機構和生產合作夥伴保持密切對話的組織，將更有能力將臨床創新轉化為永續的患者獲益。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 利用現成解決方案擴展針對固態腫瘤的同種異體CAR-T療法
  • 將鹼基編輯等基因編輯工具整合到血友病檢測中，以提高其安全性。
  • 採用新一代病毒載體提升T細胞療法的傳遞效率
  • 開發用於體內基因治療的非病毒遞送平台以降低免疫抗原性
  • 實施分散式製造模式，以全球擴大細胞療法生產規模

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按治療類型分類的細胞和基因治療臨床試驗市場

  • 細胞療法
    • CAR-T細胞
    • 樹突細胞療法
    • NK細胞療法
    • 幹細胞療法
  • 基因治療
    • 非病毒載體
      • 電穿孔
      • 脂質奈米顆粒
      • 裸露的DNA/RNA
    • 病毒載體
      • 腺結合病毒
      • 腺病毒
      • 逆轉錄病毒
  • 組織工程產品

9. 按載體類型分類的細胞和基因治療臨床試驗市場

  • 非病毒載體
    • 電穿孔
    • 脂質奈米顆粒
    • 裸露的DNA/RNA
  • 病毒載體
    • 腺結合病毒
    • 腺病毒
    • 逆轉錄病毒

第10章：按細胞類型分類的細胞和基因治療臨床試驗市場

  • 樹突狀細胞
  • NK細胞
  • 幹細胞
    • 造血幹細胞
    • 間質幹細胞
  • T細胞
    • CAR T
    • TCR

第11章：按適應症分類的細胞和基因治療臨床試驗市場

  • 神經病學
    • 阿茲海默症
    • 帕金森氏症
  • 腫瘤學
    • 血癌
      • 白血病
      • 淋巴瘤
    • 固態腫瘤
      • 乳癌
      • 黑色素瘤
  • 罕見疾病
    • 遺傳性疾病
      • 囊腫纖維化
      • 血友病
    • 代謝紊亂

第12章：按試驗階段分類的細胞和基因治療臨床試驗市場

  • 第一階段
  • 第二階段
  • 第三階段

第13章：按地區分類的細胞和基因治療臨床試驗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：細胞與基因治療臨床試驗市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：各國細胞與基因治療臨床試驗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Novartis AG
    • Gilead Sciences, Inc.
    • Spark Therapeutics, Inc.
    • bluebird bio, Inc.
    • Sangamo Therapeutics, Inc.
    • CRISPR Therapeutics AG
    • Editas Medicine, Inc.
    • Fate Therapeutics, Inc.
    • Orchard Therapeutics Ltd
    • uniQure NV
Product Code: MRR-0D217D5AEB5A

The Cell & Gene Therapy Clinical Trials Market is projected to grow by USD 32.38 billion at a CAGR of 15.14% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.48 billion
Estimated Year [2025] USD 12.08 billion
Forecast Year [2032] USD 32.38 billion
CAGR (%) 15.14%

A panoramic introduction to the clinical, manufacturing, and regulatory forces reshaping cell and gene therapy trials and strategic program choices

The cell and gene therapy clinical trials ecosystem stands at a pivotal juncture, shaped by rapid scientific maturation, evolving regulatory expectations, and shifting commercial imperatives. Over the past decade, innovations in cell engineering, viral and non-viral delivery platforms, and process analytics have translated into a broader and more diverse pipeline. As a result, programs that once focused narrowly on autologous approaches are now pursuing allogeneic strategies, refined vector design, and hybrid manufacturing models that blend decentralized and centralized capabilities.

This environment demands that stakeholders balance scientific ambition with pragmatic operational planning. Sponsors must integrate clinical development design with supply chain resilience, vector sourcing security, and manufacturing scalability. Investors and partner organizations are increasingly scrutinizing development pathways for clarity on translational risk, regulatory alignment, and commercialization readiness. Consequently, trial sponsors that align robust translational science with demonstrable manufacturing plans and regulatory engagement are better positioned to progress therapies efficiently through the clinic and toward adoption.

Given the complex interplay of biology, logistics, and policy, a holistic view that connects therapeutic modality, vector strategy, cell type selection, indication prioritization, and trial phase sequencing is essential. This report synthesizes those dimensions into a coherent narrative that supports strategic decision-making and operational execution for programs across the development lifecycle.

How breakthroughs in delivery modalities, manufacturing automation, and regulatory science are redefining clinical development pathways and commercialization readiness

The landscape of clinical development for cell and gene therapies is undergoing transformative shifts driven by advances in delivery systems, manufacturing automation, and regulatory science. Delivery technologies have expanded beyond traditional viral constructs into sophisticated non-viral approaches such as electroporation and lipid nanoparticle systems, which are enabling safer, more flexible gene transfer strategies and opening new indications. Concurrently, vector engineering and capsid design innovations are improving tissue targeting and immunogenicity profiles, encouraging clinical programs to revisit earlier decisions about modality and patient selection.

Manufacturing modernization is equally consequential. Adoption of closed systems, single-use technologies, and intensified purification strategies has raised the bar for process robustness and reproducibility. These improvements reduce batch variability and shorten cycle times, promoting the feasibility of both autologous and allogeneic models at scale. Regulatory authorities are responding by refining guidance on potency assays, comparability frameworks, and long-term follow-up requirements, which requires clinical teams to embed regulatory thinking into early-stage trial design.

Finally, commercial and clinical strategy is evolving toward indication-specific optimization. Oncology pipelines increasingly differentiate approaches between hematologic malignancies and solid tumors, while neurology and rare disease programs seek durable central nervous system delivery and single-administration treatments. Taken together, these shifts demand integrated development plans that align scientific innovation with manufacturability, regulatory pathways, and long-term patient access strategies.

Assessing the operational and strategic ripple effects of tariff-induced supply chain pressures and cost inflation on clinical trial continuity and manufacturing choices

Recent trade policy developments and tariff actions in 2025 have introduced new variables into the planning calculus for cell and gene therapy clinical programs. The cumulative effects of tariffs on critical inputs, specialized equipment, and cross-border services have elevated the importance of supply chain visibility and supplier diversification. Labs and manufacturers sourcing viral vectors, single-use consumables, and high-grade reagents are now evaluating total landed costs and lead-time volatility more rigorously, which influences decisions on domestic versus international procurement and on holding higher safety stocks for GMP materials.

In response, organizations are accelerating efforts to localize key supply chains and to qualify secondary suppliers for vector production, critical raw materials, and bioprocess equipment. This trend intersects with strategic investments in regional manufacturing capacity and contract development and manufacturing organization partnerships that reduce exposure to tariff-related disruptions. At the same time, tariff-driven cost pressure is incentivizing process optimization and yield improvement initiatives that lower per-dose material consumption and reliance on imported components.

From an operational perspective, sponsors are recalibrating clinical trial budgets to reflect increased logistics complexity, potential customs delays, and heightened costs for specialized cold-chain transportation. These adjustments influence trial site selection, enrollment strategies, and timelines for multi-regional studies. In sum, the tariff landscape underscores the need for dynamic supply chain strategies, closer collaboration with manufacturers and logistics providers, and scenario planning to maintain trial continuity and clinical momentum.

A comprehensive segmentation framework connecting modality, vector technology, cell source, indication focus, and trial phase to prioritize clinical and manufacturing strategies

A nuanced segmentation approach reveals how modality, vector technology, cellular source, indication, and clinical phase intersect to shape program risks and opportunities. Based on therapy type, the field spans cell therapy, gene therapy, and tissue-engineered products; cell therapy programs further differentiate into CAR T cell, dendritic cell therapy, NK cell therapy, and stem cell therapy, while gene therapy strategies split between non-viral and viral vectors, with non-viral options such as electroporation, lipid nanoparticle, and naked nucleic acid approaches and viral options including adeno-associated virus, adenoviral, and retroviral systems. This layered taxonomy clarifies how scientific choices influence manufacturing complexity and regulatory engagement.

Drawing from vector type segmentation, the distinction between non-viral and viral approaches is foundational to risk profiling. Non-viral methods offer advantages in manufacturability and immunogenicity control, with electroporation and lipid nanoparticle platforms enabling transient expression or precise delivery, whereas viral vectors retain strengths in efficient gene transfer and durable expression but introduce considerations around vector supply, immunological response, and capsid selection. Cell type segmentation highlights operational trade-offs; dendritic cells and NK cells present distinct potency assays and dosing paradigms, stem cells require lineage-specific handling and may be divided into hematopoietic and mesenchymal subtypes, and T cell strategies bifurcate into CAR T and TCR approaches with divergent manufacturing and clinical monitoring needs.

Indication-based segmentation underscores how therapeutic objectives define clinical design. Neurology programs targeting Alzheimer's and Parkinson's disease face blood-brain barrier delivery and long-term safety monitoring imperatives, oncology efforts must differentiate hematologic cancers such as leukemia and lymphoma from solid tumors like breast cancer and melanoma with respect to tumor microenvironment modulation, and rare disease initiatives centered on genetic and metabolic disorders such as cystic fibrosis and hemophilia prioritize durable systemic correction and newborn screening linkages. Trial phase segmentation-from Phase I through Phase III-illuminates the escalation of regulatory expectations, the increasing need for commercial-scale manufacturing plans, and the shift in evidence focus from safety and proof-of-concept toward broader efficacy, durability, and real-world applicability. Together, these segmentation lenses provide a comprehensive framework for prioritizing development investments and allocating operational resources.

How regional regulatory frameworks, manufacturing capacities, and clinical infrastructure drive differentiated development strategies across global footprints

Regional dynamics materially influence strategic decisions in trial design, manufacturing footprint, and regulatory planning. In the Americas, a mature investor base and extensive clinical infrastructure have propelled early and late-stage programs, with concentrated expertise in hematologic oncology and advanced manufacturing innovation that supports both autologous and allogeneic approaches. Regulatory engagement in this region increasingly emphasizes long-term safety monitoring and post-approval commitments, thereby shaping evidence generation plans and follow-up protocols.

Across Europe, the Middle East, and Africa, the regulatory landscape exhibits both harmonization opportunities and national nuances. European regulatory authorities and health technology assessment bodies require robust comparative effectiveness and safety data, which affects endpoint selection and companion diagnostics strategies. Meanwhile, emerging markets within these regions present attractive patient populations for rare diseases and neurology trials, but they necessitate careful planning around ethics, infrastructure readiness, and supply chain logistics.

The Asia-Pacific region is characterized by rapid capacity expansion, targeted public investment in biomanufacturing, and growing clinical trial centers with increasing experience in gene and cell therapy studies. Local regulatory frameworks are evolving to accommodate advanced therapeutics, and governments are incentivizing domestic manufacturing capabilities, which can accelerate regional access but also create competitive dynamics for intellectual property and talent. Across all regions, sponsors are balancing speed to clinic with regulatory alignment and local operational feasibility to ensure successful global development strategies.

What differentiates high-performing organizations through platform specialization, strategic manufacturing partnerships, and integrated translational-commercial planning

Leading companies and institutions in the cell and gene therapy space demonstrate strategic diversity across technology platforms, manufacturing models, and therapeutic focus areas. Some organizations concentrate on platform technologies that address vector design, capsid engineering, or non-viral delivery systems, enabling multiple programs to leverage shared R&D and process development investments. Others prioritize cell-type specialization, building deep expertise in stem cell differentiation, NK cell biology, or T cell engineering to create clinical and translational advantages in specific indications.

Partnership models have evolved to reflect operational realities; alliances with contract development and manufacturing organizations are increasingly structured as long-term strategic collaborations that include joint process optimization, technology transfer, and shared capacity planning. Companies are also investing in in-house manufacturing where control of critical quality attributes and timelines is central to their value proposition, while selectively outsourcing to maintain flexibility and cost discipline. Intellectual property strategies prioritize freedom to operate around vector platforms and delivery modalities, and many organizations are complementing core IP with data-driven assets such as biomarker signatures and digital trial endpoints to strengthen regulatory and payer dialogues.

Finally, leadership in the field often correlates with the ability to integrate translational science with commercial foresight-teams that align clinical protocols, manufacturing scale-up, and market-access planning early in development reduce downstream friction and accelerate patient access.

Priority operational recommendations to fortify supply chains, standardize platforms, and align regulatory and commercial plans for durable program success

Industry leaders should pursue a set of pragmatic, high-impact actions to navigate scientific complexity and operational constraints. First, embed supply chain resilience into program planning by qualifying multiple vector and critical-material suppliers, investing in strategic inventory buffers for GMP consumables, and evaluating regional manufacturing partnerships that reduce exposure to trade disruptions. Second, accelerate platform harmonization: standardize core unit operations, assay panels, and potency metrics across portfolios to reduce development timelines and simplify comparability assessments.

Third, align early regulatory engagement with clinical and manufacturing decisions. Initiate timely dialogues with regulators to clarify long-term follow-up expectations, comparability criteria, and requirements for novel delivery systems. Fourth, prioritize scalable process improvements that reduce material consumption and increase yield; even modest gains in vector or cell yield can materially reduce downstream logistical burden and cost sensitivity. Fifth, structure commercial strategies that anticipate payer evidence needs by integrating health economics endpoints and real-world data collection into pivotal study designs and post-approval plans.

Lastly, cultivate cross-functional capability by investing in teams that bridge biology, process engineering, regulatory affairs, and market access. This organizational coherence enables faster decision-making under uncertainty, smoother technology transfers, and more defensible positioning in negotiations with partners and payers. Implementing these actions will support both near-term trial continuity and long-term commercialization success.

A robust mixed-methods approach combining expert interviews, regulatory review, and scenario analysis to deliver program-specific and operationally actionable insights

The research methodology underpinning this analysis combines qualitative synthesis of clinical development trends, regulatory guidance review, and cross-industry operational practices to produce actionable insights. Primary inputs included structured interviews with clinical development leaders, manufacturing and supply chain executives, and regulatory affairs specialists, supplemented by peer-reviewed literature, regulatory communications, and product-specific technical disclosures. The analysis emphasized triangulation across sources to validate observed shifts in delivery technologies, process improvements, and regional capacity expansion.

Analysts applied a segmentation framework that integrates therapy modality, vector type, cell biology, indication focus, and trial phase to ensure that recommendations are context-sensitive and operationally relevant. Scenario analysis was used to assess the implications of trade policy changes, supply chain shocks, and manufacturing innovations on trial continuity and program economics. Wherever possible, methodological transparency was maintained by documenting assumptions about supply chain dependencies, regulatory timelines, and technology readiness levels.

Limitations of the methodology are acknowledged: rapidly evolving clinical data and proprietary manufacturing practices can alter program trajectories, and regional regulatory decisions may shift in response to new evidence. To mitigate these constraints, the approach emphasizes regularly updated advisories and the option for customized deep-dive analyses tailored to specific programs and partnership scenarios.

A concise synthesis of strategic imperatives that reconcile scientific innovation with operational resilience to advance clinical programs and patient access

In conclusion, the clinical trials landscape for cell and gene therapies is at an inflection point where scientific opportunity converges with heightened operational complexity. Progress in delivery technologies, vector engineering, and manufacturing automation creates pathways to broader therapeutic impact, yet these gains are accompanied by supply chain fragility, regulatory scrutiny, and the need for scaled manufacturing solutions. Sponsors that proactively integrate modality selection, vector strategy, cell-source considerations, indication-specific design, and phase-appropriate evidence generation will navigate development risks more effectively.

Regional dynamics and recent trade policy developments further underscore the importance of resilient supply chains, diversified manufacturing footprints, and carefully sequenced regulatory engagement. Achieving program success requires harmonizing translational science with process development and commercial foresight, and assembling cross-functional teams capable of executing on complex, interconnected objectives. Ultimately, organizations that prioritize standardization where possible, preserve flexibility where necessary, and maintain close dialogue with regulators and manufacturing partners will be best positioned to translate clinical innovation into sustainable patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of allogeneic CAR-T therapies targeting solid tumors with off-the-shelf solutions
  • 5.2. Integration of gene editing tools like base editing to increase safety in hemophilia trials
  • 5.3. Adoption of next-generation viral vectors to improve transduction efficiency in T-cell therapies
  • 5.4. Development of non-viral delivery platforms for in vivo gene therapies to reduce immunogenicity
  • 5.5. Implementation of decentralized manufacturing models to scale cell therapy production globally

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Clinical Trials Market, by Therapy Type

  • 8.1. Cell Therapy
    • 8.1.1. CAR T Cell
    • 8.1.2. Dendritic Cell Therapy
    • 8.1.3. NK Cell Therapy
    • 8.1.4. Stem Cell Therapy
  • 8.2. Gene Therapy
    • 8.2.1. Non-Viral Vector
      • 8.2.1.1. Electroporation
      • 8.2.1.2. Lipid Nanoparticle
      • 8.2.1.3. Naked DNA/RNA
    • 8.2.2. Viral Vector
      • 8.2.2.1. Adeno-Associated Virus
      • 8.2.2.2. Adenoviral
      • 8.2.2.3. Retroviral
  • 8.3. Tissue Engineered Products

9. Cell & Gene Therapy Clinical Trials Market, by Vector Type

  • 9.1. Non-Viral Vector
    • 9.1.1. Electroporation
    • 9.1.2. Lipid Nanoparticle
    • 9.1.3. Naked DNA/RNA
  • 9.2. Viral Vector
    • 9.2.1. Adeno-Associated Virus
    • 9.2.2. Adenoviral
    • 9.2.3. Retroviral

10. Cell & Gene Therapy Clinical Trials Market, by Cell Type

  • 10.1. Dendritic Cell
  • 10.2. NK Cell
  • 10.3. Stem Cell
    • 10.3.1. Hematopoietic Stem Cell
    • 10.3.2. Mesenchymal Stem Cell
  • 10.4. T Cell
    • 10.4.1. CAR T
    • 10.4.2. TCR

11. Cell & Gene Therapy Clinical Trials Market, by Indication

  • 11.1. Neurology
    • 11.1.1. Alzheimer Disease
    • 11.1.2. Parkinson Disease
  • 11.2. Oncology
    • 11.2.1. Hematologic Cancer
      • 11.2.1.1. Leukemia
      • 11.2.1.2. Lymphoma
    • 11.2.2. Solid Tumor
      • 11.2.2.1. Breast Cancer
      • 11.2.2.2. Melanoma
  • 11.3. Rare Disease
    • 11.3.1. Genetic Disorder
      • 11.3.1.1. Cystic Fibrosis
      • 11.3.1.2. Hemophilia
    • 11.3.2. Metabolic Disorder

12. Cell & Gene Therapy Clinical Trials Market, by Trial Phase

  • 12.1. Phase I
  • 12.2. Phase II
  • 12.3. Phase III

13. Cell & Gene Therapy Clinical Trials Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell & Gene Therapy Clinical Trials Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell & Gene Therapy Clinical Trials Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. Gilead Sciences, Inc.
    • 16.3.3. Spark Therapeutics, Inc.
    • 16.3.4. bluebird bio, Inc.
    • 16.3.5. Sangamo Therapeutics, Inc.
    • 16.3.6. CRISPR Therapeutics AG
    • 16.3.7. Editas Medicine, Inc.
    • 16.3.8. Fate Therapeutics, Inc.
    • 16.3.9. Orchard Therapeutics Ltd
    • 16.3.10. uniQure N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CELL & GENE THERAPY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CELL & GENE THERAPY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE